Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 22, 2025
Catalent, Inc. announced a strategic collaboration with Galapagos NV to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.
read more
Wednesday, January 11, 2017
Catalent Pharma Solutions has announced that it is to evaluate Jupiter Orphan Therapeutics, Inc.’s (JOT) novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology. Under the agreement, Catalent will ...
read more
Friday, December 16, 2022
Catalent announced that it is to establish a new biologics analytical center of excellence in Durham, within North Carolina’s Research Triangle, to offer comprehensive standalone analytical development and testing for biologic drug modalities, ...
read more
Catalent announced a multi-year $350 million investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities. The project will serve the industry’s robust biologics pipeline across ...
read more
Wednesday, April 25, 2018
Catalent Pharma Solutions announced it plans to invest $5 million in the creation of a new drug development CoE at its Somerset, New Jersey facility and headquarters.
read more
Catalent is set to launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs.
read more
Wednesday, January 20, 2016
Catalent Pharma Solutions has announced that it is to introduce clinical supply services at its 200,000 sq. ft. cGMP facility in Kakegawa, Japan.
read more
Thursday, September 05, 2019
Catalent announced it will invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.
read more
Tuesday, November 13, 2018
Catalent Pharma Solutions announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019.
read more
Wednesday, December 04, 2019
Catalent has entered into a partnership with Ethicann, a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate prescription drugs.
read more
Catalent Biologics announced a long-term strategic agreement for the development and manufacturing of Zolgensma®, an AveXis gene therapy treatment for spinal muscular atrophy.
read more
Wednesday, October 19, 2016
Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that it is to provide fill-finish production services for the commercial supply ...
read more
Wednesday, September 26, 2018
GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of proprietary APIs for its Parkinson’s disease therapies
read more
Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
read more
Friday, November 22, 2019
Catalent has entered into a long-term commercial supply agreement with BeiGene.
read more